47 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
12565952	26	p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones.	Merck
12482438	50	p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold.	Merck Research Laboratories
9873730	27	Potent inhibitors of the MAP kinase p38.	R. W. Johnson Pharmaceutical Research Institute
9873686	18	Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.	Smithkline Beecham Pharmaceuticals
26259807	21	Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.	Sejong University
25965804	80	Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.	Eli Lilly
25893042	65	Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.	Translational Research Institute
25415535	118	Inhibitors of c-Jun N-terminal kinases: an update.	Eberhard Karls Universit£T T£Bingen
25369539	116	SAR156497, an exquisitely selective inhibitor of aurora kinases.	Sanofi
12672248	50	Kinase inhibitors: not just for kinases anymore.	Northwestern University
12166950	208	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.	Millennium Pharmaceuticals
11844702	14	Pyridazine based inhibitors of p38 MAPK.	Merck Research Laboratories
11591521	39	Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach.	Bayer Research Center
16789733	41	Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.	Bristol-Myers Squibb Pharmaceutical Research Institute
16516473	444	Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.	Astrazeneca
16216497	67	Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.	Abbott Bioresearch Center
15615512	21	Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.	Bristol-Myers Squibb Pharmaceutical Research Institute
15317463	16	Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.	Bristol-Myers Squibb Pharmaceutical Research Institute
14592495	60	Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).	Bristol-Myers Squibb Pharmaceutical Research Institute
12672234	64	Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.	Boehringer Ingelheim Pharmaceuticals
12565927	24	Imidazopyrimidines, potent inhibitors of p38 MAP kinase.	Johnson & Johnson Pharmaceutical Research and Development
12540232	53	Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.	Merck Research Laboratories
11934592	24	Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.	Merck Research Laboratories
11549467	85	Substituted imidazoles as glucagon receptor antagonists.	Merck Research Laboratories
30792101	3	Design and molecular modeling of novel P38? MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.	National Research Centre
26914744	24	Chemical Space of DNA-Encoded Libraries.	University of Utah
31550662	109	Progress in the development of more effective and safer analgesics for pain management.	University of Catania
9873604	72	Pyrroles and other heterocycles as inhibitors of p38 kinase.	Merck Research Laboratory
31188592	39	Why Some Targets Benefit from beyond Rule of Five Drugs.	Boston University
28291685	12	Synthesis and molecular docking studies of new furochromone derivatives as p38? MAPK inhibitors targeting human breast cancer MCF-7 cells.	Cairo University
23941661	5	KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space.	Vu University Amsterdam
24332487	46	Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors.	The Scripps Research Institute
23746475	93	The identification of novel p38? isoform selective kinase inhibitors having an unprecedented p38? binding mode.	Bristol-Myers Squibb Pharmaceutical Research Institute
18157122	1	High-content single-cell drug screening with phosphospecific flow cytometry.	Stanford University
17095218	3	Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: a new use of silicon bioisosteres in medicinal chemistry.	Paradigm Therapeutics
17411025	12	Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.	Eberhard-Karls-University T£Bingen
16945534	7	p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold.	Merck Research Laboratories
16750367	2	The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.	Procter and Gamble Pharmaceuticals
15139749	35	Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.	Procter and Gamble Pharmaceuticals
12852754	143	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.	Eberhard-Karls-University T£Bingen
12061876	53	From imidazoles to pyrimidines: new inhibitors of cytokine release.	Eberhard-Karls-University T£Bingen
12014955	19	An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.	Aventis Pharma
11585447	16	Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system.	Vertex Pharmaceuticals
29291937	40	Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.	Takeda Pharmaceutical
29107542	35	Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.	Novartis Institutes For Biomedical Research
29133046	18	Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer.	University of Zagreb